Contributions
Abstract: PB1889
Type: Publication Only
Background
B-cell chronic lymphocytic leukemia (CLL) is the most common haematological malignancy in advanced age. The clinical course of the disease is highly variable, therefore there is a need to investigate the various prognostic factors. The CLL cell typically expresses CD5, CD19, CD23 and a monoclonal surface Ig (K or λ) while CD20 is moderately/weakly expressed.
Aims
We aimed to analyze the clinical, genetic and immunophenotypic features which might have prognostic value in CLL.
Methods
Between February 2010 and June 2018, 87 cases diagnosed with CLL were retrospectively analyzed. Patients who were followed without treatment (T0 group) and who required at least one line treatment (T) were compared. Patients who required 1 line treatment (T1) were also further compared with patients who required >1 line treatment (T2). Statistical analyzes were performed using chi-square test using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA). A value of less than 0.05 was considered significant.
Results
The mean age of our patient population was 65 ( ±SD12,8) with Male/Female 56/31. At diagnosis, 68(78.2%) patients were at early stage (0, I, II) and 19 (21.8%) were at advanced stage (III,IV). Del17p, del13q and trisomy 12 were evaluated in 49, 41 and 31 patients and 5, 13 and 4 patients were found out to be positive, respectively. Anemia and thrombocytopenia were present in 25 (28.7%) and 16 (18.4%) patients, respectively. Twenty one (24.1%) patients had B symptoms. Splenomegaly, lymphadenopathy and hepatomegaly were present in 34(39%), 67(77%) and 21(24.1%) patients, respectively. Four of the 15 patients who had direct coombs positivity also had clinical evidence of hemolytic anemia. Four patients had immune thrombocytopenia, 2 of them had concurrent direct coombs positivity and one also had hemolytic anemia. The median Hb, leukocyte and platelet counts were 13.2 gr/dl (4.4-17.5 gr/dl), 23.6 x 109/L (1,7-527 x 109/L) and 200 x109/L (10-345 109/L), respectively. Follow up period was median 38 months (3-180 months). Twenty five (28.7%) patients were treated at the time of diagnosis. Thirty three (37.9%) patients had T1 and 6 (6.9%) patients required T2. The ratio of male patients in group T were significantly higher than female patients (p=0.038). All patients in group T2 were male. More patients in group T had CD38 expression than group T0 (p=0.04). There was no significant difference between the groups in terms of FMC7 and CD11c expressions. Of the 5 patients with del17p, 2 patients required treatment at diagnosis, 2 patients required treatment after 13 and 48 months of follow up, respectively.
Conclusion
In our CLL patients, requirement for treatment was associated with CD38 expression, del17p positivity at diagnosis and male gender.
Session topic: 6. Chronic lymphocytic leukemia and related disorders - Clinical
Keyword(s): CD38, Chronic Lymphocytic Leukemia, Gender
Abstract: PB1889
Type: Publication Only
Background
B-cell chronic lymphocytic leukemia (CLL) is the most common haematological malignancy in advanced age. The clinical course of the disease is highly variable, therefore there is a need to investigate the various prognostic factors. The CLL cell typically expresses CD5, CD19, CD23 and a monoclonal surface Ig (K or λ) while CD20 is moderately/weakly expressed.
Aims
We aimed to analyze the clinical, genetic and immunophenotypic features which might have prognostic value in CLL.
Methods
Between February 2010 and June 2018, 87 cases diagnosed with CLL were retrospectively analyzed. Patients who were followed without treatment (T0 group) and who required at least one line treatment (T) were compared. Patients who required 1 line treatment (T1) were also further compared with patients who required >1 line treatment (T2). Statistical analyzes were performed using chi-square test using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA). A value of less than 0.05 was considered significant.
Results
The mean age of our patient population was 65 ( ±SD12,8) with Male/Female 56/31. At diagnosis, 68(78.2%) patients were at early stage (0, I, II) and 19 (21.8%) were at advanced stage (III,IV). Del17p, del13q and trisomy 12 were evaluated in 49, 41 and 31 patients and 5, 13 and 4 patients were found out to be positive, respectively. Anemia and thrombocytopenia were present in 25 (28.7%) and 16 (18.4%) patients, respectively. Twenty one (24.1%) patients had B symptoms. Splenomegaly, lymphadenopathy and hepatomegaly were present in 34(39%), 67(77%) and 21(24.1%) patients, respectively. Four of the 15 patients who had direct coombs positivity also had clinical evidence of hemolytic anemia. Four patients had immune thrombocytopenia, 2 of them had concurrent direct coombs positivity and one also had hemolytic anemia. The median Hb, leukocyte and platelet counts were 13.2 gr/dl (4.4-17.5 gr/dl), 23.6 x 109/L (1,7-527 x 109/L) and 200 x109/L (10-345 109/L), respectively. Follow up period was median 38 months (3-180 months). Twenty five (28.7%) patients were treated at the time of diagnosis. Thirty three (37.9%) patients had T1 and 6 (6.9%) patients required T2. The ratio of male patients in group T were significantly higher than female patients (p=0.038). All patients in group T2 were male. More patients in group T had CD38 expression than group T0 (p=0.04). There was no significant difference between the groups in terms of FMC7 and CD11c expressions. Of the 5 patients with del17p, 2 patients required treatment at diagnosis, 2 patients required treatment after 13 and 48 months of follow up, respectively.
Conclusion
In our CLL patients, requirement for treatment was associated with CD38 expression, del17p positivity at diagnosis and male gender.
Session topic: 6. Chronic lymphocytic leukemia and related disorders - Clinical
Keyword(s): CD38, Chronic Lymphocytic Leukemia, Gender